英: mechanism-based inhibition

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ステロイド療法を受けている患者の術前のマネージメントthe management of the surgical patient taking glucocorticoids [show details]
…to glucocorticoid dosing is based upon the likelihood of hypothalamic-pituitary axis (HPA) suppression and the magnitude of the surgical stress. In addition to suppression of the HPA axis, perioperative …
2. 分化型甲状腺癌：マネージメントの概要differentiated thyroid cancer overview of management [show details]
…minimize potential TSH stimulation of tumor growth. Our approach for initial thyroid hormone suppression is based upon risk of disease recurrence : American Thyroid Association (ATA) low risk – For patients …
3. ガンシクロビルおよびバルガンシクロビル：概要ganciclovir and valganciclovir an overview [show details]
… Empiric dose adjustments for valganciclovir can be based upon measured or estimated creatinine clearance (CrCl) : ≥60 mL/min: Usual dose (ie,… Ganciclovir and valganciclovir are both associated with bone marrow suppression,… medications with well-known nephrotoxicity, such as cyclosporine, has been a frequent confounder . The mechanism of nephrotoxicity is unknown, and the risk associated with ganciclovir per se appears to be low …
4. 成人の炎症性腸疾患患者へのブデソニド療法の概要overview of budesonide therapy for adults with inflammatory bowel disease [show details]
…be used for treating patients with Crohn disease, and the choice between the two formulations is based on availability . Colonic release formulation – This formulation of multimatrix budesonide extends … formulation compared with placebo (RR 1.09, 95% CI 0.95-1.26) . Systemic adverse effects (eg, adrenal suppression, decreased bone mass) occur less often in patients treated with budesonide compared with conventional …
5. 炎症性腸疾患へのアザチオプリン、メルカプトプリンの投与の概要overview of azathioprine and mercaptopurine use in inflammatory bowel disease [show details]
…dosing based on thiopurine-S-methyltransferase (TPMT) genotype or enzymatic activity (phenotype) testing. The authors use empiric, gradual dosing with target doses that are generally weight-based .… The mechanism of action of azathioprine is discussed in more detail separately.… laboratory monitoring does not always prevent bone marrow suppression or hepatotoxicity,…

Related Pictures

「CKD診療ガイドライン2018」を発表糖尿病性腎臓病(DKD)など新 54. 大脳辺縁系と行動選択モデルのまとめ - 論文・レポート [試験研究課題]白樺成分ベツリンのがん免疫抑制解除作用に DNA発現のスイッチ、脱メチル化機構を解明 ― 骨代謝制御の免疫抑制剤：国際腎臓病ガイドラインに基づく ”患者さんの TCR－Nckの相互作用のブロックに基づく免疫抑制剤【最新医療】次世代がん治療薬の効果「見える化」に成功国立ホスホジエステラーゼ阻害薬 - Phosphodiesterase inhibitor - JapaneseClass.jp